Approval · Notice of Compliance 21249 · 2018
CONSTELLA: Notice of Compliance 21249
Issued August 28, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21249
- Date
- August 28, 2018
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CONSTELLA | Not yet assigned | — |
Medicinal ingredients
- LINACLOTIDE 72 MCG per CAP
- LINACLOTIDE 145 MCG per CAP
- LINACLOTIDE 290 MCG per CAP